Gene editing techniques such as CRISPR-Cas9 enable the generation of both small and large genetic alterations.
TLA analyses, using primers in proximity to a targeted site, can be used to determine what sequence changes have occurred in that locus.
In addition, TLA analyses can, using transgene-specific primer pairs, be used to determine the exact sequence of desired and (un)desired integration events of any transgene sequence.
See below to watch a replay of a recent webinar on the complete genetic characterisation of transgenes, integration sites and gene editing events.
"TLA analysis has proven to be very useful to quality control genetically engineered cell lines”
Dr. John Wiseman - Associate Director (Molndal, Sweden)
"TLA has proven to be a powerful technology for transgene integration site sequencing and for evaluation of structural changes in the transgene and/or integration site.”
Ludwig Maximilians University Munich
Dr. Nik Klymiuk - Molecular Animal Breeding and Biotechnology (Germany)
"TLA outperforms traditional methods used in CHO cell-line characterisation and provides higher resolution and sensitivity.”
Dr. Stefanie Bartels - Project Leader - Cell Line Development (The Netherlands)
"TLA is a highly efficient method for mapping the insertion site of any transgene.”
Dr. Søren Warming - Associate Director/Senior Scientist (San Francisco, CA, USA)
"Cergentis quickly determined transgene insertion for three out of three lines along with providing information on deletions and rearrangements in chromosomal DNA at the site. The service was quick, accurate and reasonably priced, and reports were complete and helpful.”
Prof. Dr. Joshua Sanes - Department of Molecular and Cellular Biology (Cambridge, MA, USA)
- Application notes
Application note on TLA-based transgene and -integration site sequencing.
Leidy-Davis T et al. (2018)
A*STAR, Duke-NUS Medical School, Duke University Medical Center, The Jackson Laboratory, Nanyang Technological University, National Cancer Centre Singapore & Singapore General Hospital
Lu Q et al. (2017)
GlaxoSmithKline & Wellcome Trust Sanger Institute
Eyquem J et al. (2017)
Memorial Sloan Kettering Cancer Center & Sloan Kettering Institute
Renaud J-B et al. (2016)
Amagen, CHU de Nantes, genOway & Museum National d'Histoire Naturelle